Matthew A. Hunt

Matthew A. Hunt

Auto-generated profile, based on publicly available information

Matthew A. Hunt

Department of Physiology and Pharmacology, Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Neuron
Verified
Journal Article
Closed access
PLPaul Lu
Paul Lu
GWGrace Woodruff
Grace Woodruff
YWYaozhi Wang
Yaozhi Wang
LGLori Graham
Lori Graham
MHMatt Hunt
Matt Hunt
MTMark H. Tuszynski
Mark H. Tuszynski

10 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AMAna M. Moreno
Ana M. Moreno
FAFernando Alemán
Fernando Alemán
GCGlaucilene F. Catroli
Glaucilene F. Catroli
MHMatthew Hunt
Matthew Hunt
MHMichael Hu
Michael Hu
PMPrashant Mali
Prashant Mali
In situ genome targeting of Na V 1.7 via CRISPRs and zinc fingers enables genomically scarless, durable, and nonaddictive management of pain.

20 December 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HLHarald Lund
Harald Lund
MHMatthew A. Hunt
Matthew A. Hunt
ZKZerina Kurtović
Zerina Kurtović
KSKatalin Sandor
Katalin Sandor
PKPaul B. Kägy
Paul B. Kägy
CSCamilla I. Svensson
Camilla I. Svensson
In dorsal root ganglia (DRG), macrophages reside close to sensory neurons and have largely been explored in the context of pain, nerve injury, and repair. However, we discovered that most DRG macrophages interact with and monitor the vasculature by sampling macromolecules from the blood. Characterization of the DRG vasculature revealed a specialized endothelial bed that transformed in molecular, structural, and permeability properties along the arteriovenous axis and was covered by macrophage-interacting pericytes and fibroblasts. Macrophage phagocytosis spatially aligned with peak endothelial permeability, a process regulated by enhanced caveolar transcytosis in endothelial cells. Profiling the DRG immune landscape revealed two subsets of perivascular macrophages with distinct transcriptome, turnover, and function. CD163+ macrophages self-maintained locally, specifically participated in vasculature monitoring, displayed distinct responses during peripheral inflammation, and were conserved in mouse and man. Our work provides a molecular explanation for the permeability of the blood–DRG barrier and identifies an unappreciated role of macrophages as integral components of the DRG-neurovascular unit.

1 November 2021 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
HHHiroshi Hoshijima
Hiroshi Hoshijima
MHMatthew Hunt
Matthew Hunt
HNHiroshi Nagasaka
Hiroshi Nagasaka
TYTony Yaksh
Tony Yaksh
Acetaminophen (APAP) in humans has robust effects with a high therapeutic index in altering postoperative and inflammatory pain states in clinical and experimental pain paradigms with no known abuse potential. This review considers the literature reflecting the preclinical actions of acetaminophen in a variety of pain models. Significant observations arising from this review are as follows: 1) acetaminophen has little effect upon acute nociceptive thresholds; 2) acetaminophen robustly reduces facilitated states as generated by mechanical and thermal hyperalgesic end points in mouse and rat models of carrageenan and complete Freund’s adjuvant evoked inflammation; 3) an antihyperalgesic effect is observed in models of facilitated processing with minimal inflammation (eg, phase II intraplantar formalin); and 4) potent anti-hyperpathic effects on the thermal hyperalgesia, mechanical and cold allodynia, allodynic thresholds in rat and mouse models of polyneuropathy and mononeuropathies and bone cancer pain. These results reflect a surprisingly robust drug effect upon a variety of facilitated states that clearly translate into a wide range of efficacy in preclinical models and to important end points in human therapy. The specific systems upon which acetaminophen may act based on targeted delivery suggest both a spinal and a supraspinal action. Review of current targets for this molecule excludes a role of cyclooxygenase inhibitor but includes effects that may be mediated through metabolites acting on the TRPV1 channel, or by effect upon cannabinoid and serotonin signaling. These findings suggest that the mode of action of acetaminophen, a drug with a long therapeutic history of utilization, has surprisingly robust effects on a variety of pain states in clinical patients and in preclinical models with a good therapeutic index, but in spite of its extensive use, its mechanisms of action are yet poorly understood.

1 October 2017 in Experimental Neurology
Verified
Journal Article
Closed access
MHMatthew Hunt
Matthew Hunt
PLPaul Lu
Paul Lu
MTMark H. Tuszynski
Mark H. Tuszynski

6 February 2025 in The Journal of Pain
Verified
Journal Article
Open access
JJJenny E. Jakobsson
Jenny E. Jakobsson
JMJoana Menezes
Joana Menezes
EKEmerson Krock
Emerson Krock
MHMatthew A. Hunt
Matthew A. Hunt
HCHenrik Carlsson
Henrik Carlsson
KKKim Kultima
Kim Kultima
Autoimmunity and immunoglobulin G (IgG) autoantibodies may contribute to pain in a subset of fibromyalgia (FM) patients. Previously, IgG from FM patients was found to induce pain-like behavior in mice and bind to satellite glial cells (anti-SGC IgG). The anti-SGC IgG levels were also associated with more severe symptomatology. Lipid metabolism in FM subjects is altered with lysophosphatidylcholines (LPCs) acting as pain mediators. The relationship between autoantibodies, lipid metabolism, and FM symptomatology remains unclear. Serum lipidomics with liquid chromatography mass spectrometry, anti-SGC IgG levels, and clinical measures were examined in 35 female FM subjects and 33 age- and body mass index-balanced healthy controls (HC). Fibromyalgia subjects with higher anti-SGC IgG levels experienced more intense pain than those with lower levels. Sixty-three lipids were significantly altered between FM subjects and HC or between FM subjects with severe (FM severe) and mild symptoms (FM mild). Compared to HC, FM subjects had lower concentrations of lipid species belonging to the classes LPC (n = 10), lysophosphatidylethanolamine (n = 7), phosphatidylcholine (n = 4), and triglyceride (n = 5), but higher concentrations of diglyceride (n = 3). Additionally, FM severe had higher LPC 19:0, 22:0, and 24:1 and lower sphingomyelin (n = 9) concentrations compared to FM mild. Positive associations were seen for LPC 22:0 and 24:1 with pain intensity and anti-SGC IgG levels in FM subjects. Taken together, these results suggest an association between altered lipid metabolism and autoimmune mechanisms in FM.